Mirtazapine for Sleep: Evidence, Side Effects, and Safety

Mirtazapine can make some people drowsy, and a prescriber may sometimes choose it when sleep problems occur alongside depression or in selected cases of insomnia. That does not make it an approved or universally suitable insomnia treatment.

In the United States, mirtazapine is FDA-approved to treat major depressive disorder in adults. It is not FDA-approved for insomnia, obsessive-compulsive disorder, or anxiety disorders. Using it specifically to improve sleep is off-label ¹.

The practical question is not simply whether mirtazapine causes sleepiness. It is whether its likely benefits fit the cause of a person's insomnia and outweigh its adverse effects and interactions.

Sedation is not the same as treating insomnia

Mirtazapine blocks histamine H1 receptors, an action that may help explain its prominent sedating effect. In the trials used for its depression approval, somnolence was a common adverse effect. The FDA label also says it is unclear whether people develop tolerance to that somnolence ¹.

Feeling sleepy after a dose does not prove that the medication will produce durable, restorative sleep or treat the process causing chronic insomnia. A person may fall asleep more easily yet still have untreated sleep apnea, restless legs syndrome, a circadian rhythm problem, medication-related sleep disruption, or insomnia maintained by conditioned wakefulness and worry.

Mirtazapine's sedating effect may be noticeable early for some people, but there is no reliable timetable that predicts when an individual will sleep better, whether the effect will continue, or whether next-day impairment will outweigh it.

What direct insomnia trials found

Direct evidence for mirtazapine in people diagnosed with insomnia is newer and much smaller than its evidence base for depression.

The DREAMING trial enrolled 80 adults in Dutch primary care who had insomnia disorder with sleep-maintenance problems and had not improved enough with non-drug care. Compared with placebo, the mirtazapine group had a clinically relevant improvement in insomnia severity at six weeks. That advantage was no longer present from 12 weeks onward. The trial therefore supports a possible short-term effect in this selected group, not a general claim that mirtazapine remains effective for months or years ².

The MIRAGE trial studied 60 adults age 65 and older with chronic insomnia at one Canadian geriatric outpatient clinic. After 28 days, the mirtazapine group improved more than the placebo group on insomnia severity and sleep-diary measures. Six people receiving mirtazapine stopped treatment because of adverse effects, compared with one person receiving placebo ³.

These randomized trials are useful, but each was small and tested a specific regimen in a defined population. One showed benefit only at the early assessment, and the other lasted four weeks. Neither establishes long-term effectiveness or long-term safety for chronic insomnia.

The 2023 European insomnia guideline allows that sedating antidepressants may be considered off-label for short-term treatment in selected cases after contraindications are considered. It also emphasizes that evidence is insufficient for broad recommendations about longer medication use ⁴.

Insomnia with depression is a different treatment question

When major depression and insomnia occur together, a clinician may choose mirtazapine to treat the depression while considering its effects on sleep, appetite, weight, and daytime function. That is different from prescribing it solely for insomnia in a person without depression.

Improvement in sleep during depression treatment can be meaningful, but it should not be separated from the full psychiatric response and safety plan. Worsening mood, agitation, unusual behavior, or signs of mania can change the decision even if sleep initially improves.

Claims that mirtazapine reliably increases restorative deep sleep or reduces REM sleep are too strong. One often-cited sleep-laboratory pilot included only six adults with depression and followed them for two weeks. Sleep continuity improved, but REM measures did not change significantly. That study cannot establish a lasting sleep-stage benefit or predict what happens in primary insomnia ⁵.

What should be evaluated before using it for sleep

Chronic insomnia deserves an evaluation of the pattern and likely cause, not only a search for a sedating medication. A clinician may ask about:

• loud snoring, witnessed pauses in breathing, gasping, morning headaches, or marked daytime sleepiness that could point to obstructive sleep apnea
• an evening urge to move the legs, uncomfortable leg sensations, or repeated limb movements
• a sleep schedule that is consistently shifted later or earlier than the required schedule
• alcohol, cannabis, caffeine, nicotine, stimulants, sedatives, and other substances
• prescription and nonprescription medicines that can affect sleep or interact with mirtazapine
• pain, menopause symptoms, thyroid disease, breathing problems, depression, anxiety, trauma, or bipolar symptoms
• pregnancy, breastfeeding, falls, memory problems, kidney or liver disease, seizures, heart rhythm risk, and other factors that can alter the safety decision

The 2025 VA/DoD guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for chronic insomnia and favors it over medication as the starting approach. It also advises checking for other sleep disorders, daytime sleepiness, substance use, impairment, and medication interactions before short-term drug treatment ⁶.

CBT-I is a structured treatment, not a list of generic sleep-hygiene tips. Sleep hygiene may support care, but the guideline recommends against using it as a stand-alone treatment for chronic insomnia ⁶. Medication does not need to replace CBT-I when a clinician decides both have a role.

Dose, timing, and formulation are prescriber-led

There is no standard mirtazapine dose that is appropriate for every person using it off-label for sleep. The right prescription depends on why it was selected, other conditions and medicines, previous response, adverse effects, age, and kidney or liver function.

The popular claim that lower doses are reliably more sedating than higher doses is not established well enough to guide self-adjustment. A retrospective analysis of adverse-event reports did not support the expected pattern of greater activating effects at higher doses. The study cannot define the best dose for insomnia, but it illustrates why the simple low-dose-equals-more-sedation rule should not be treated as fact ⁷.

Take the exact product, dose, and schedule prescribed. Do not change the dose or timing to chase sleepiness. Standard tablets and orally disintegrating tablets also have different handling instructions, so splitting, crushing, or switching formulations should be cleared with the prescriber or pharmacist ¹.

Common side effects and next-day impairment

In the depression trials summarized by the FDA, common adverse effects included drowsiness, increased appetite, weight gain, dry mouth, constipation, and dizziness ¹. The balance can be very different from one person to another. For example, increased appetite may be helpful in one clinical situation and a reason to choose another medication in a different one.

Drowsiness can continue into the next day and impair thinking, judgment, coordination, and reaction time. Do not drive or operate dangerous equipment until you know how the medication affects you. Dizziness and sedation can also increase concern about falls, especially in older adults or when getting up during the night ¹.

Alcohol and benzodiazepines can add to mirtazapine's cognitive and motor impairment. Other sedating medicines may also compound drowsiness. A pharmacist or prescriber should review the complete list, including nonprescription drugs and supplements, rather than assuming a combination is safe ¹.

Less common but important safety issues

Mirtazapine is an antidepressant, so its safety discussion extends beyond ordinary sleep-aid side effects.

• Mood and behavior: The antidepressant boxed warning describes an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults in short-term studies. Mirtazapine is not approved for pediatric patients. People of any age should be monitored for clinical worsening, suicidal thinking, or unusual behavior, particularly early in treatment and after dose changes. Screening for bipolar disorder matters because an antidepressant can precipitate mania or hypomania. New suicidal thoughts or an immediate safety concern require urgent help ¹.
• Serotonin syndrome and interactions: Combining mirtazapine with other serotonergic drugs can raise the risk of serotonin syndrome. Agitation, confusion, fever, sweating, diarrhea, muscle rigidity, tremor, or poor coordination require prompt medical assessment. Monoamine oxidase inhibitors have specific contraindications and timing restrictions that must be managed by a prescriber ¹.
• Low sodium: Hyponatremia can cause headache, confusion, weakness, memory difficulty, and unsteadiness. Severe cases can cause seizures, fainting, breathing problems, coma, or death. Older adults, people taking diuretics, and people who are volume depleted may be at higher risk ¹.
• Infection symptoms: Rare severe neutropenia or agranulocytosis has been reported. Fever, chills, sore throat, mouth sores, or other signs of infection should be reported promptly so the prescriber can decide whether blood testing or a medication change is needed ¹.
• Eyes, seizures, and heart rhythm: Mirtazapine can trigger angle-closure glaucoma in susceptible people and should be used cautiously with a seizure disorder. QT prolongation and serious rhythm events have been reported, particularly with overdose or other risk factors. New severe eye pain or visual changes, a seizure, fainting, or concerning palpitations warrants urgent assessment ¹.

Older adults may clear mirtazapine more slowly and may be more vulnerable to confusion, oversedation, low sodium, and falls. Reduced kidney or liver function can also lower drug clearance. Pregnancy and breastfeeding decisions require an individualized discussion of medication exposure and the risks of untreated depression. None of these situations should be managed by changing the prescription independently ¹.

A new urge to move the legs at rest, unpleasant evening leg sensations, or kicking that fragments sleep is also worth discussing. A systematic review found that new or worsened restless legs symptoms were uncommon with antidepressants overall, but the limited prospective evidence suggested mirtazapine may carry a higher risk than some other antidepressants ⁸.

Stopping mirtazapine is not a do-it-yourself taper

Discontinuation symptoms do not by themselves mean addiction, but they do mean mirtazapine should not be stopped abruptly without clinical direction. Symptoms can include dizziness, abnormal dreams, agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, sweating, and unusual sensory symptoms. Return of insomnia or depression can also be mistaken for, or occur alongside, discontinuation effects ¹.

The FDA label recommends gradual dose reduction rather than abrupt cessation, but it does not supply one taper schedule that fits everyone. The prescriber should plan each change based on the current dose, formulation, duration of use, reason for treatment, and response.

Questions to ask before deciding

A useful medication discussion is specific to the person and the problem:

• Is the main goal treatment of major depression, short-term insomnia relief, or both?
• Has the insomnia pattern been assessed for sleep apnea, restless legs, circadian timing, and substance or medication effects?
• Is CBT-I available, and how will it fit into the plan?
• Which adverse effects would make the balance unfavorable?
• How will mood, daytime alertness, weight, falls, interactions, and sleep response be monitored?
• When will the need for the medication be reviewed, and who should be contacted before any dose or formulation change?

Mirtazapine may be a reasonable clinician-selected option in some cases, particularly when depression and insomnia coexist. The evidence does not support treating its sedating effect as proof of a durable insomnia therapy. A clear diagnosis, CBT-I when appropriate, a medication-specific safety review, and a planned follow-up point provide a stronger basis for deciding whether the benefits are worth the risks.